Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report details a specific share repurchase transaction executed on September 10, 2012, authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 1,800,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 10, 2012.
- Price Range: Highest price paid was 1,418.5 pence per share; lowest price paid was 1,392.5 pence per share.
- Treasury Holdings (Settled): 507,932,427 shares (9.28% of total issued share capital).
- Treasury Holdings (Including Unsettled): 513,015,427 shares (10.33% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,964,417,300 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,800,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.28% of issued capital and 10.33% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (507,932,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.33% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Review the remaining authorization for share buybacks under the mandate granted on May 3, 2012.
- Note that this filing does not contain operational or financial performance data for the period.